G-CSF

G-CSF 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Acute-On-Chronic Liver Failure、Alcoholic Hepatitis、Liver Cirrhosis, Alcoholic、Graft-Versus-Host Disease。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

24 项

全球在招研究

3 项

已进入 III/IV 期

18 个

开展国家和地区

有

中国境内设点

药品与企业信息

研发企业

Yaqrit Ltd
National Heart, Lung, and Blood Institute (NHLBI)
Masonic Cancer Center, University of Minnesota
Assistance Publique - Hôpitaux de Paris
Blokhin's Russian Cancer Research Center
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
N.N. Petrov National Medical Research Center of Oncology
Fred Hutchinson Cancer Center

汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。

生产企业

公开药品批准资料或正式说明书暂未提供明确的生产企业信息。

研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。

主要开展国家和地区

美国、法国、Russia、意大利、中国、澳大利亚、比利时、加拿大、丹麦、爱尔兰、荷兰、新西兰

正在招募患者的 G-CSF 研究

中国患者怎么争取用上这款药

这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。

同类方向的其他在研新药

Carboplatin Pembrolizumab Cyclophosphamide Rituximab Venetoclax Azacitidine Dexamethasone Doxorubicin

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。

G-CSF

药品与企业信息

研发企业

生产企业

主要开展国家和地区

正在招募患者的 G-CSF 研究

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline

Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia

High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Low Dose Induction for Pediatric Acute Myeloid Leukemia Patients

Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

中国患者怎么争取用上这款药

同类方向的其他在研新药